Endocrinology

Overweight/obese patients with elevated fasting blood glucose generally present with higher degrees of insulin resistance, inflammation, adverse cardiovascular disease risk profile.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

New data show liraglutide reduced visceral, ectopic fat, with greater effects seen compared to weight loss.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

A systematic review of clinical trials notes that topical eye drops may lead to favorable retinal and visual outcomes, despite heterogeneity across multiple studies.

The indication makes the Novo Nordisk product the first weekly injection GLP-1 agonist approved for managing overweight and obesity.

The EMDAC voted 10-7 to support the benefit-risks of teplizumab for delaying clinical type 1 diabetes.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.

The smart pen cap system is associated with real-time hypoglycemia alerts and insulin dose recommendations.

Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.

A new study finds the top 10 future research priorities into diabetes and pregnancy.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

New data show dasiglucagon a reliable and rapid treatment in restoring plasma glucose levels.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

The rates of both diseases have been increasingly linked in recent years.

The SGLT2 inhibitor is the first of its class to receive indication for treating kidney outcomes regardless of a patient's diabetes status.

A cohort analysis of African American patients finds an association between 1-year ozone concentrations and diagnosed incident diabetes at clinical visit.

New data show a link between body mass index and increased risk of adverse effects from COVID-19.

New data show that youths with type 1 diabetes perceive their sleep as disrupted, but investigators find similar objective outcomes in youths without diabetes.

Men, individuals with 15 years of type 2 diabetes, and those older than 55 years old had the greatest absolute risk reduction.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

A new study on dapagliflozin use finds consistent risk reduction in treatment of patients with higher rates of kidney dysfunction.

The study represents the first to examine a PPD connection to allopregnanolone.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

An expert physician in cardiology and metabolic management walks through a presentation on identifying, addressing, and continually treating for heightened cardiometabolic risk.

Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.